Adjuvant or neoadjuvant therapy for operable esophagogastric cancer?

Gastric Cancer

Volumn 18, Issue 1, 2015, Pages 1-10

  Moorcraft, Sing Yu ^a   Smyth, Elizabeth C ^a   Cunningham, David ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Chemoradiotherapy; Chemotherapy; Esophageal cancer; Gastric cancer; Standard of care

Indexed keywords

CAPECITABINE; CISPLATIN; EPIRUBICIN; FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; OXALIPLATIN;

ASIAN; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECHOGRAPHY; ESOPHAGOGASTRIC ADENOCARCINOMA; ESOPHAGUS CANCER; FATIGUE; GASTRECTOMY; GENETIC POLYMORPHISM; HUMAN; LAPAROSCOPY; LEUKOPENIA; LOWER ESOPHAGUS SPHINCTER; NEUTROPENIA; OVERALL SURVIVAL; PHARMACOGENOMICS; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; REVIEW; STOMACH CANCER; VOMITING; ADENOCARCINOMA; ADJUVANT CHEMORADIOTHERAPY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ASIA; CLINICAL TRIAL (TOPIC); ESOPHAGEAL NEOPLASMS; EUROPE; MORTALITY; NEOPLASMS, SQUAMOUS CELL; PATHOLOGY; STOMACH NEOPLASMS; TREATMENT OUTCOME; TUMOR RECURRENCE; UNITED STATES;

ADENOCARCINOMA; ASIA; CHEMORADIOTHERAPY, ADJUVANT; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; EUROPE; HUMANS; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SQUAMOUS CELL; POSITRON-EMISSION TOMOGRAPHY; STOMACH NEOPLASMS; TREATMENT OUTCOME; UNITED STATES;

EID: 84916198530     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-014-0356-0     Document Type: Review

References (35)

1. Lauren P. The two main histological types of gastic carcinoma. Acta Pathol Microbiol Scand. 1965;64:31–49 Epub 1965/01/01.
2. Marrelli D, Roviello F, de Manzoni G, Morgagni P, Di Leo A, Saragoni L, et al. Different patterns of recurrence in gastric cancer depending on Lauren’s histological type: longitudinal study. World J Surg. 2002;26(9):1160–5.
3. Tan IB, Ivanova T, Lim KH, Ong CW, Deng N, Lee J, et al. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology. 2011;141(2):476–85. doi:10.1053/j.gastro.2011.04.042.
4. Okines A, Verheij M, Allum W, Cunningham D, Cervantes A. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol: Off J Eur Soc Med Oncol/ESMO. 2010;21(Suppl 5):v50–4. doi:10.1093/annonc/mdq164 (PubMed PMID: 20555102).
5. Stahl M, Budach W, Meyer HJ, Cervantes A. Esophageal cancer: clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol: Off J Eur Soc Med Oncol/ESMO. 2010;21(Suppl 5):v46–9. doi:10.1093/annonc/mdq163.
6. Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, Negri E, et al. Recent patterns in gastric cancer: a global overview. Int J Cancer. 2009;125(3):666–73.
7. Wu H, Rusiecki JA, Zhu K, Potter J, Devesa SS. Stomach carcinoma incidence patterns in the united states by histologic type and anatomic site. Cancer Epidemiol Biomark Prev. 2009;18(7):1945–52. doi:10.1158/1055-9965.epi-09-0250.
8. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315–21. doi:10.1016/s0140-6736(11)61873-4 (Epub 2012/01/10 PubMed PMID: 22226517).
9. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. New Engl J Med. 2001;345(10):725–30. doi:10.1056/NEJMoa010187 (Epub 2001/09/08, PubMed PMID: 11547741).
10. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New Engl J Med. 2006;355(1):11–20. doi:10.1056/NEJMoa055531.
11. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol: Off J Am Soc Clin Oncol. 2011;29(33):4387–93. doi:10.1200/jco.2011.36.5908 (Epub 2011/10/20, PubMed PMID: 22010012).
12. Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol: Off J Am Soc Clin Oncol. 2011;29(13):1715–21. doi:10.1200/JCO.2010.33.0597.
13. Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol: Off J Am Soc Clin Oncol. 2010;28(35):5210–8. doi:10.1200/JCO.2009.26.6114 (PubMed PMID: 21060024; PubMed Central PMCID: PMC3020693).
14. Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27(30):5062–7. doi:10.1200/jco.2009.22.2083.
15. Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, et al. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol: Off J Am Soc Clin Oncol. 2007;25(24):3719–25. doi:10.1200/JCO.2006.10.4760.
16. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8(3):226–34. doi:10.1016/s1470-2045(07)70039-6.
17. Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA: J Am Med Assoc. 2010;303(17):1729–37. doi:10.1001/jama.2010.534 (Epub 2010/05/06, PubMed PMID: 20442389).
18. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. New Engl J Med. 2007;357(18):1810–20. doi:10.1056/NEJMoa072252 (Epub 2007/11/06, PubMed PMID: 17978289).
19. Noh SH, Park SR, Yang H-K, Chung HC, Chung I-J, Lee KH, et al. Adjuvant capecitabine and oxaliplatin (XELOX) for gastric cancer after D2 gastrectomy: final results from the CLASSIC trial. Ann Oncol. 2013;24(Suppl 4):iv14. doi:10.1093/annonc/mdt201.7.
20. Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;. doi:10.1200/jco.2011.36.7136.
21. Lee J, Lim DH, Kim S, Park SH, Park JO, Park YS, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30(3):268–73. doi:10.1200/jco.2011.39.1953.
22. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. New Engl J Med. 1996;335(7):462–7. doi:10.1056/NEJM199608153350702.
23. Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005;6(9):659–68. doi:10.1016/S1470-2045(05)70288-6.
24. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer H-J, Riera-Knorrenschild J, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27(6):851–6. doi:10.1200/jco.2008.17.0506.
25. Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, et al. Phase III trial of trimodality therapy with cisplatin, Fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26(7):1086–92. doi:10.1200/jco.2007.12.9593.
26. van Hagen P, Hulshof MCCM, van Lanschot JJB, Steyerberg EW, Henegouwen MIVB, Wijnhoven BPL, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. New Engl J Med. 2012;366(22):2074–84.
27. van Hagen P, Wijnhoven BP, Nafteux P, Moons J, Haustermans K, De Hertogh G, et al. Recurrence pattern in patients with a pathologically complete response after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer. Br J Surg. 2013;100(2):267–73. doi:10.1002/bjs.8968.
28. Oppedijk V, van der Gaast A, van Lanschot JJ, van Hagen P, van Os R, van Rij CM, et al. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. J Clin Oncol: Off J Am Soc Clin Oncol. 2014;. doi:10.1200/JCO.2013.51.2186.
29. zum Buschenfelde CM, Herrmann K, Schuster T, Geinitz H, Langer R, Becker K, et al. (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. J Nucl Med. 2011;52(8):1189–96. doi:10.2967/jnumed.110.085803 (Epub 2011/07/19, PubMed PMID: 21764790).
30. Krause BJ, Herrmann K, Wieder H, zum Buschenfelde CM. 18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer. J Nucl Med. 2009;50(Suppl 1):89–96. doi:10.2967/jnumed.108.057232.
31. Smyth E, Schoder H, Strong VE, Capanu M, Kelsen DP, Coit DG, et al. A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-d-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer. Cancer. 2012;. doi:10.1002/cncr.27550 (Epub 2012/05/03, PubMed PMID: 22549558).
32. Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol. 2006;24(29):4692–8. doi:10.1200/jco.2006.06.7801.
33. Lordick F, Ott K, Krause B-J, Weber WA, Becker K, Stein HJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007;8(9):797–805. doi:10.1016/S1470-2045(07)70244-9.
34. Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97. doi:10.1016/s0140-6736(10)61121-x.
35. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. New Engl J Med. 1998;339(27):1979–84. doi:10.1056/NEJM199812313392704.